STOCK TITAN

Atyr Pharma Inc - LIFE STOCK NEWS

Welcome to our dedicated news page for Atyr Pharma (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on Atyr Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atyr Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atyr Pharma's position in the market.

Rhea-AI Summary
aTyr Pharma to present corporate overview at H.C. Wainwright Global Investment Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
-
Rhea-AI Summary
aTyr Pharma, Inc. announced second quarter 2023 results and provided a corporate update. They are currently enrolling patients for the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. They expect to initiate the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the third quarter of 2023. The company ended the second quarter with $112.0 million in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
Rhea-AI Summary
aTyr Pharma will present on its lead therapeutic candidate, efzofitimod, at the World Association for Sarcoidosis and Other Granulomatous Disorders Conference. Efzofitimod is an investigational treatment with a novel myeloid-cell focused mechanism that downregulates inflammatory responses. The Phase 3 EFZO-FIT study is enrolling patients with pulmonary sarcoidosis and is expected to be the largest interventional study in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
Atyr Pharma Inc

Nasdaq:LIFE

LIFE Rankings

LIFE Stock Data

118.22M
60.12M
2.62%
61.73%
0.64%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About LIFE

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation